Cullinan Therapeutics(CGEM) Stock Price Today

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

JonesTrading Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $34
Moomoo NewsMar 13 14:32 ET · Ratings
Cullinan Oncology Coverage Assumed by Morgan Stanley at Overweight
Dow JonesMar 7 12:32 ET
Morgan Stanley Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $35
Moomoo NewsMar 7 09:31 ET · Ratings
Express News | Cullinan Therapeutics : Morgan Stanley Cuts Target Price to $35.00 From $38.00
ReutersMar 7 07:44 ET
Morgan Stanley Initiates Cullinan Therapeutics(CGEM.US) With Buy Rating, Announces Target Price $35
Moomoo NewsMar 7 07:31 ET · Ratings
Stifel Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Cuts Target Price to $30
Moomoo NewsFeb 28 09:31 ET · Ratings

Comments

Teddy123

Feb 27 20:12

Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

$Cullinan Therapeutics (CGEM.US)$
Cullinan's Zipalertinib Hits Primary Endpoint: What Does This Mean for Its $606.9M War Chest?

Jaguar8

Oct 16, 2024 19:38

NEWS

$Cullinan Therapeutics (CGEM.US)$
Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus
Cullinan Therapeutics (Nasdaq: CGEM) announced FDA clearance of its Investigational New Drug (IND) Application for CLN-978, allowing its global Phase 1 clinical trial to proceed in the U.S. for patients with moderate to severe systemic lupus erythematosus (SLE). CLN-9...

1

Jaguar8

Apr 24, 2024 22:10

$Cullinan Therapeutics (CGEM.US)$
NEWS
Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024

Moomoo Breakfast US

May 12, 2022 20:18

Columns Today's pre-market stock movers: BYND, DIS, F, GM and more

Gainers:
• $Cullinan Therapeutics (CGEM.US)$ +22.4% (Cullinan Management and Taiho Pharmaceutical to collaborate to jointly develop and commercialize CLN081/TAS6417 and Taiho's acquisition of Cullinan Pearl)
• $Lordstown Motors (RIDE.US)$ +17.2% (closes asset purchase agreement with Foxconn)
• $Applovin (APP.US)$ +15.5%(In reaction to earnings)
• $SmartRent (SMRT.US)$ +15.4%(In reaction to earnings)
• $Coupang (CPNG.US)$ +14.3%(In reaction to earn...

12

3

OldNormanBates

Jan 6, 2021 19:38

$Cullinan Therapeutics (CGEM.US)$ ISO this week in Biotech Pharma.

CGEM Cullinan Therapeutics

Trade Overview

Capital Trend

News

Comments

Trending Stocks